| 1 |
Wang LQ, Bone JN, Muraca GM, et al. Prepregnancy body mass index and other risk factors for early-onset and late-onset haemolysis, elevated liver enzymes and low platelets (HELLP) syndrome: a population-based retrospective cohort study in British Columbia, Canada[J]. BMJ Open, 2024, 14 (3): e079131.
|
| 2 |
Ma K, Berger D, Reau N. Liver diseases during pregnancy[J]. Clin Liver Dis, 2019, 23 (2): 345-361.
|
| 3 |
Li BY, Yang HX. Comparison of clinical features in antepartum and postpartum HELLP syndrome[J]. Zhonghua Fu Chan Ke Za Zhi, 2022, 57 (12): 907-913.
|
| 4 |
van Lieshout LCEW, Koek GH, Spaanderman MA, et al. Placenta derived factors involved in the pathogenesis of the liver in the syndrome of haemolysis, elevated liver enzymes and low platelets (HELLP): a review[J]. Pregnancy Hypertens, 2019, 18: 42-48.
|
| 5 |
Akaishi T, Tarasawa K, Hamada H, et al. Prenatal hypertension as the risk of eclampsia, HELLP syndrome, and critical obstetric hemorrhage[J]. Hypertens Res, 2024, 47 (2): 455-466.
|
| 6 |
Adorno M, Maher-Griffiths C, Grush Abadie HR. HELLP syndrome[J]. Crit Care Nurs Clin North Am, 2022, 34 (3): 277-288.
|
| 7 |
Weinstein L. Syndrome of hemolysis, elevated liver enzymes, and low platelet count: a severe consequence of hypertension in pregnancy[J]. Am J Obstet Gynecol, 1982, 142 (2): 159-167.
|
| 8 |
Poimenidi E, Metodiev Y, Archer NN, et al. Haemolysis, elevated liver enzymes and low platelets: diagnosis and management in critical care[J]. J Intensive Care Soc, 2022, 23 (3): 372-378.
|
| 9 |
刘俊英.常见孕产妇危急重症种类及其诊断标准[J].吉林医药学院学报，2020，41（6）：424-425.
|
| 10 |
Giannubilo SR, Marzioni D, Tossetta G, et al. HELLP syndrome and differential diagnosis with other thrombotic microangiopathies in pregnancy[J]. Diagnostics (Basel), 2024, 14 (4): 352.
|
| 11 |
Petca A, Miron BC, Pacu I, et al. HELLP syndrome—holistic insight into pathophysiology[J]. Medicina (Kaunas), 2022, 58 (2): 326.
|
| 12 |
Akalin SA, Ocal E, Deveci E. Role of SOX9 and Hif-1α expression in placentas of patients with HELLP[J]. Acta Cir Bras, 2023, 38: e388023.
|
| 13 |
Burwick RM, Feinberg BB. Complement activation and regulation in preeclampsia and hemolysis, elevated liver enzymes, and low platelet count syndrome[J]. Am J Obstet Gynecol, 2022, 226 (2S): S1059-S1070.
|
| 14 |
Scully M, Neave L. Etiology and outcomes: thrombotic microangiopathies in pregnancy[J]. Res Pract Thromb Haemost, 2023, 7 (2): 100084.
|
| 15 |
Lokki AI, Haapio M, Heikkinen-Eloranta J. Eculizumab treatment for postpartum HELLP syndrome and aHUS—case report[J]. Front Immunol, 2020, 11: 548.
|
| 16 |
Gardikioti A, Venou TM, Gavriilaki E, et al. Molecular advances in preeclampsia and HELLP syndrome[J]. Int J Mol Sci, 2022, 23 (7): 3851.
|
| 17 |
Palomo M, Blasco M, Molina P, et al. Complement activation and thrombotic microangiopathies[J]. Clin J Am Soc Nephrol, 2019, 14 (12): 1719-1732.
|
| 18 |
Chen S, Li Z, He Y, et al. Dysregulation of complement system in HELLP syndrome[J]. Hypertens Pregnancy, 2021, 40 (4): 303-311.
|
| 19 |
Bazzan M, Todros T, Tedeschi S, et al. Genetic and molecular evidence for complement dysregulation in patients with HELLP syndrome[J]. Thromb Res, 2020, 196: 167-174.
|
| 20 |
Li W, Zhou L, Kang S. Expression of insulin-like growth factor binding protein-3 in HELLP syndrome[J]. BMC Pregnancy Childbirth, 2023, 23 (1): 778.
|
| 21 |
Gibbens J, Spencer SK, Solis L, et al. Fas ligand neutralization attenuates hypertension, endothelin-1, and placental inflammation in an animal model of HELLP syndrome[J]. Am J Physiol Regul Integr Comp Physiol, 2020, 319 (2): R195-R202.
|
| 22 |
von Salmuth V, van der Heiden Y, Bekkers I, et al. The role of hepatic sinusoidal obstruction in the pathogenesis of the hepatic involvement in HELLP syndrome: exploring the literature[J]. Pregnancy Hypertens, 2020, 19: 37-43.
|
| 23 |
Gong L, Zhao H, Cui Y, et al. Transcriptome analysis of placentae reveals HELLP syndrome exhibits a greater extent of placental metabolic dysfunction than preeclampsia[J]. Hypertens Pregnancy, 2021, 40 (2): 134-143.
|
| 24 |
Sandvoβ M, Potthast AB, von Versen-Hoynck F, et al. HELLP syndrome[J]. Reprod Sci, 2017, 24 (4): 568-574.
|
| 25 |
Abildgaard U, Heimdal K. Pathogenesis of the syndrome of hemolysis, elevated liver enzymes, and low platelet count (HELLP): a review[J]. Eur J Obstet Gynecol Reprod Biol, 2013, 166 (2): 117-123.
|
| 26 |
Rath W, Tsikouras P, Stelzl P. HELLP syndrome or acute fatty liver of pregnancy: a differential diagnostic challenge: common features and differences[J]. Geburtshilfe Frauenheilkd, 2020, 80 (5): 499-507.
|
| 27 |
Alese MO, Moodley J, Naicker T. Preeclampsia and HELLP syndrome, the role of the liver[J]. J Matern Fetal Neonatal Med, 2021, 34 (1): 117-123.
|
| 28 |
袁琳，刘兴会. HELLP综合征的处理[J].实用妇产科杂志，2022，38（12）：899-901.
|
| 29 |
Young S, Wang MJ, Srivastava A, et al. Intrapartum magnesium sulfate exposure and obstetric hemorrhage risk[J]. J Matern Fetal Neonatal Med, 2022, 35 (25): 10036-10043.
|
| 30 |
杨怡珂，漆洪波.美国妇产科医师学会（ACOG）"妊娠期高血压和子痫前期指南2019版"要点解读（第一部分）[J].中国实用妇科与产科杂志，2019（8）：895-899.
|
| 31 |
刘云. HELLP综合征并肝损害1例并文献复习[J].临床荟萃，2024，39（7）：644-649.
|
| 32 |
余登辉，杜虹，姜泓，等.糖皮质激素在病毒性脓毒症中的作用[J/OL].中华危重症医学杂志（电子版），2024，17（3）：245-250.
|
| 33 |
Anez-Aguayo MY, Vigil-De Gracia P. Dexamethasone in HELLP syndrome: experience in Bolivia[J]. J Matern Fetal Neonatal Med, 2020, 33 (1): 1-4.
|
| 34 |
高霞. HELLP综合征的诊治进展[J].中国城乡企业卫生，2021，36（7）：42-44.
|
| 35 |
李爽，程波，王强，等.血小板与内皮细胞屏障功能[J/OL].中华危重症医学杂志（电子版），2019，12（1）：56-60.
|
| 36 |
Arigita Lastra M, Martínez Fernández GS. HELLP syndrome: controversies and prognosis[J]. Hipertens Riesgo Vasc, 2020, 37 (4): 147-151.
|
| 37 |
李政，陈倩.走在HELLP综合征发病前一步以避免惨烈结局[J].中国实用妇科与产科杂志，2024，40（8）：779-784.
|
| 38 |
Wallace K, Harris S, Addison A, et al. HELLP syndrome: pathophysiology and current therapies[J]. Curr Pharm Biotechnol, 2018, 19 (10): 816-826.
|
| 39 |
Chowdhry M, Agrawal S, Gajulapalli SP, et al. Therapeutic plasma exchange in HELLP syndrome: a life savior[J]. Asian J Transfus Sci, 2022, 16 (1): 106-110.
|
| 40 |
Amirlatifi S, Kooshari Z, Salmani K, et al. Evaluation of long noncoding RNA (LncRNA) in pathogenesis of HELLP syndrome: diagnostic and future approach[J]. J Obstet Gynaecol, 2023, 43 (1): 2174836.
|
| 41 |
王斌霞，唐莲，李兰. 1例抗磷脂综合征合并HELLP综合征患者肾脏替代治疗期间的抗凝治疗分析和药学监护[J].中国药师，2022，25（6）：1040-1044.
|
| 42 |
朱玥，黄晓娜. 1例产科抗磷脂综合征并发HELLP综合征患者的抗凝治疗分析与药学监护[J].药物流行病学杂志，2024，33（2）：218-223.
|
| 43 |
龙尚琴.小剂量阿司匹林联合低分子肝素对抗磷脂抗体阳性妊娠合并慢性高血压患者妊娠结局的影响[D].大连：大连医科大学，2023.
|
| 44 |
Dighriri IM, Al-Qahtani RM, Almutairi AO, et al. Iptacopan efficacy and safety to treat paroxysmal nocturnal hemoglobinuria (PNH): a systematic review and meta-analysis[J]. Cureus, 2024, 16 (8): e67830.
|
| 45 |
Garnier A, Brochard K, Kwon T, et al. Efficacy and safety of eculizumab in pediatric patients affected by shiga toxin-related hemolytic and uremic syndrome: a randomized, placebo-controlled trial[J]. J Am Soc Nephrol, 2023, 34 (9): 1561-1573.
|
| 46 |
Stojanovska V, Zenclussen AC. Innate and adaptive immune responses in HELLP syndrome[J]. Front Immunol, 2020, 11: 667.
|
| 47 |
Lu JF, Hu ZQ, Yang MX, et al. Downregulation of PDGF-D inhibits proliferation and invasion in breast cancer MDA-MB-231 cells[J]. Clin Breast Cancer, 2022, 22 (2): e173-e183.
|
| 48 |
张甜甜，李静，田珍.血小板源性生长因子在湿性年龄相关性黄斑变性新生血管及纤维化中的作用研究进展[J].眼科新进展，2024，44（5）：410-414.
|
| 49 |
Wang H, Nian L, Li Z, et al. Inhibiting PDGF-D alleviates the symptoms of HELLP by suppressing NF-κB activation[J]. J Mol Endocrinol, 2021, 66 (3): 233-243.
|
| 50 |
Kaltofen T, Grabmeier J, Weissenbacher T, et al. Liver rupture in a 28-year-old primigravida with superimposed pre-eclampsia and hemolysis, elevated liver enzyme levels, and low platelet count syndrome[J]. J Obstet Gynaecol Res, 2019, 45 (5): 1066-1070.
|
| 51 |
马擘，崔洪艳，陈叙.子痫前期诊治新进展[J/OL].中华危重症医学杂志（电子版），2019，12（5）：353-357.
|
| 52 |
Tseke P, Tsekes P, Griveas I. Use of therapeutic apheresis methods during pregnancy[J]. Transfus Apher Sci, 2024, 63 (1): 103848.
|